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Abstract
Background: Economic evaluation of stroke services indicates that such services may lead to improved quality of
life at affordable cost. The present study assesses lifetime health impact and cost consequences of stroke in an
integrated service setting.
Methods: The EDISSE study is a prospective non-randomized controlled cluster trial that compared stroke services
(n = 151 patients) to usual care (n = 187 patients). Health status and cost trial-data were entered in multi-
dimensional stroke life-tables. The tables distinguish four levels of disability which are defined by the modified
Rankin scale. Quality-of-life scores (EuroQoL-5D), transition and survival probabilities are based on concurrent Dutch
follow-up studies. Outcomes are quality-adjusted life years lived and lifetime medical cost by disability category. An
economic analysis compares outcomes from a successful stroke service to usual care, by bootstrapping individual
costs and effects data from patients in each arm.
Results: Lifetime costs and QALYs after stroke depend on age-of-onset of first-ever stroke. Lifetime QALYs after
stroke are 2.42 (90% CI - 0.49 - 2.75) for male patients in usual care and 2.75 (-0.61; 6.26) for females. Lifetime costs
for men in the usual care setting are €39,335 (15,951; 79,837) and €42,944 (14,081; 95,944) for women. A
comparison with the stroke service results in an ICER of €11,685 saved per QALY gained (€14,211 and €7,745 for
men and women respectively). This stroke service is with 90% certainty cost-effective.
Conclusions: Our analysis shows the potential of large health benefits and cost savings of stroke services, taking a
lifetime perspective, also in other European settings.
Background
In The Netherlands, as in most Western countries,
stroke is a major contributor to the total burden of dis-
ease, in terms of morbidity, mortality and concomitant
costs. In 2007, incidence of primary stroke was 2.12 per
1,000 men and 2.23 per 1,000 women, prevalence of
stroke was 11.89 per 1,000 men and 11.48 per 1,000
women, and mortality from stroke was 46.50 per
100,000 men and 69.84 per 100,000 women [1]. The
incidence rates in the Netherlands have only fluctuated
around the same level since the early 1990 s. Yet, mor-
tality has been steadily declining [1].
The burden of stroke in the Netherlands is compar-
able to that in other Western countries [2]. As a result,
in 2005 stroke was a top-5 disease in terms of costs,
with a total of 1.5 billion Euros. This accounts for 2.2%
of total health care costs in the Netherlands [3].
The total burden of disease from stroke is expected to
increase. In 20 years, the prevalence of stroke in the
Netherlands will be more than 40% higher as a result of
aging of the population, continuing unhealthy lifestyles
among elderly, and improved care for stroke patients
leading to lower mortality [1]. Several studies investi-
gated future trends in life expectancy and disability after
stroke in the Netherlands. Struijs et al. [4], used a
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dynamic single-state life-table combining demographic
projections and existing stroke incidence and mortality
data, and projected a 30% rise in life years lost between
2000 and 2020. Niessen et al. [5] estimated future stroke
morbidity rates using a disability-based two-state transi-
tion model combining population projections and exist-
ing data on stroke epidemiology. Their projections
indicated that the aging of the population and the
increase in cardiovascular survival would partially miti-
gate the effect of the declining incidence on the total
burden of stroke, leading to a further increase in major
stroke prevalence among the oldest age groups.
An important contribution to increased survival rates
after stroke is provided by better coordinated care,
including rehabilitation and treatment of complications,
through widespread implementation of stroke units, as
recommended by the American Heart Association. Inte-
grated stroke services are expected to enhance the early
state effect of stroke unit treatment. We characterise
integrated stroke services as formal arrangements and
strict coordination between various providers of stroke
care, with the aim to “provide the right care, to the
right patient at the right time”. Stroke Services are
multi-facetted and need different adaptations in different
regional settings. It may be difficult to determine which
aspects of stroke services lead to the reported better
health outcomes [6-8]. Notable elements of stroke ser-
vices are: protocolised care, early rehabilitation, preven-
tion of early complications, early supported discharge
and secondary prevention. Positive health effects have
not only been reported for stroke services as a whole,
but also for each of these elements separately [6-9].
Reports on stroke services are more ambiguous on
changes in costs [10-14]. The services tend to be cost-
effective on the short term compared to traditional care.
The short horizon of these findings complicates the for-
mulation of clear recommendations on stroke services.
The risks of disability associated with stroke can be high
and the chances of new cardiovascular events, stroke or
other, are high. Longer survival and these negative
health effects may be associated with considerable health
care costs. It is unclear whether the positive health
effects and potential cost savings will persist in the long
run. Consequently, additional evidence on the relative
cost-effectiveness of stroke services is needed for longer
time horizons.
To our knowledge no long-term follow-up study has
reported the cost-effectiveness of stroke services. Long-
term results do exist for stroke unit care in the United
Kingdom. Using a stratified Markov model Saka et al.
showed that stroke unit care combined with early sup-
ported discharge provided better health at acceptable
costs up to ten years after stroke [15]. In addition, the
Department of Health reported cost-effective results for
stroke units and early supported discharge, again with a
ten year time horizon [16]. However, these results apply
to early stage stroke services and do not incorporate
continuity of care outside the hospital.
In summary, current evidence shows stroke services to
be attractive, yet little is known about the effect of
stroke service implementation on long-term mortality,
disability and costs. The purpose of the present study is
to examine the lifetime cost-effectiveness of stroke ser-
vices as compared to conventional stroke care, using a
life-table approach, differentiating four post-stroke dis-
ability categories, assuming persisting health effects.
This has required an increase of the disability categories
applied in our earlier multi-dimensional life-table study,
also used in the evaluation of stroke guidelines [5,17].
Methods
Selection of patients
The study used a selection of data from a recent empiri-
cal cohort in the Netherlands, the EDISSE study (Eva-
luation of Dutch Integrated Stroke Service Experiments)
[14]. The trial was approved by all participating institu-
tions’ ethics committees which was documented in the
trial registration (ISRCTN67636203). This prospective
non-randomized controlled cluster trial assessed the
cost-effectiveness of three stroke service experiments
between 1999 and 2000 compared to conventional
stroke care in the Netherlands. A stroke service was
defined as an integration of a hospital stroke unit with
nursing homes, rehabilitation centres, GP’s and home
care providers to provide adequate services in all stages
of the follow-up process [14].
The three trial regions represented the full variety of
stroke service care in The Netherlands. Trial and con-
trol regions were comparable in terms of case mix; their
selection was based on similarity with national stroke
statistics in terms of age, length of hospital stay, case-
fatality, functional status at discharge, and destination
after discharge. The research populations compare well
to the demographic profile of the Netherlands. Trained
nurses collected data from medical files in hospital and
through follow-up patient/proxy interviews two and six
months after stroke. Reliability and internal validity
were guaranteed by reassessment of files by colleagues
or neurologists.
Intervention contrast
Here, data from one of the three experiments, a stroke
service in Delft, was compared to data from all three
control regions. This stroke service was a collaboration
of a single hospital with an integrated stroke unit; a nur-
sing home with capacity for all diagnosed patients to be
admitted and a home care organization with specially
trained nurses for stroke patients. In addition, the three
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organizations made formal mutual agreements about
patient flows and continuity of care. Furthermore, home
care nurses received additional training and a trans-
mural stroke nurse was in charge of patient transfers.
This was the only fully integrated stroke service as
defined ex ante, and was the only one cost-effective in
the first six months after stroke in the EDISSE trial,
while the other did not comply to these criteria and
showed indifferent results [14].
The control settings reflected the usual stroke care in
The Netherlands at the time (e.g. concerning case load,
length of stay and extent of illness). In some settings
stroke units were already (being) developed at different
care locations in the region, both in hospitals and in
rehabilitation centres but not in nursing homes. How-
ever, there were no implemented formal agreements
between care providers or regular consultations between
stroke care providers.
The care process in stroke services differs in many
aspects from usual care. This makes the introduction of
stroke service a complex intervention. The effects take
place within a ‘black box’ and it will be difficult to iden-
tify the effects of single aspect of the stroke service.
Table 1 presents the characteristics of the EDISSE study
population.
Disability-stratified stroke life-table
A life-table approach was applied to extrapolate the trial
findings and to arrive at estimates of lifetime health bene-
fits and costs per patient. A multidimensional Markov
structure with four disability categories was adopted,
based on the modified Rankin scale (mRS) [17]: category
1 (mRS 0-1); 2 (mRS 2-3); 3 (mRS 4) and 4 (mRS 5).
Between these categories significant differences in quality
of life exist (see figure 1a). These EQ-5 D ranges are
mutually exclusive and show that the two additional dis-
ability categories allow for better measurement of health
effects than in the original model. Like with EuroQoL-5
D scores, the mRS was not administered at baseline, and
Barthel scores were used to classify patients into the four
stroke disability categories at baseline (see Figure 1b):
Barthel scores 20; 14-19; 5-13 and 0-4 were assigned to
category 1, 2, 3 and 4 respectively. This mapping scheme
resulted in the least misclassified patients after two and
six months of follow-up.
In the multidimensional life-table, patients can move
between disability categories depending on the outcomes
of stroke recurrence and recovery (see Additional file 1).
Patient flows between the four disability categories were
based on various epidemiological estimates (see Table 2).
Patients exit the life-table only when they die or reach
the age of 100. We divided deaths into four categories,
each with its own age-specific rates. Clearly, deaths occur
because of the stroke itself either (i) immediately after
stroke or (ii) from its complications in a later stage. Since
stroke patients face higher probabilities of cardiovascular
events other than stroke, we modelled (iii) deaths result-
ing from other cardiovascular events separately. Finally,
patients can leave the model because of any other, (iv)
non-related cause of death. All death, incidence and
recurrences rates are stroke severity specific and based
either directly on original epidemiological data or are
adjusted through a hazard ratio (see table 2). All transi-
tions are assumed to take place at the end of each cycle
of six months. In our life time perspective a half cycle
correction is unnecessary as the effects hardly influence
the life-time results. All parameters - i.e., the risk of
recurrence, case-fatality rate of stroke, probability of dis-
ability after stroke, and the four probabilities of death -
affect patients’ courses in the same way as they did in the
original life-table model [5]. The annual probability of a
vascular event was assumed constant over time [18].
The life-table was written in Microsoft Excel, and had
the following sequence of calculations: (i) transition
Table 1 Characteristics of the study population
Stroke service Usual care
N entire EDISSE population 151 187
N with full six month follow-up 90 114
Age 72 73
Women 43 (48%) 65 (57%)
Low educational level (primary school or lower) 34 (38%) 18 (16%)
Living alone at home before stroke 25 (28%) 40 (35%)
Previous stroke 30 (33%) 33 (29%)
Lowered level of consciousness according to Glasgow Coma Scale 3 (3%) 4 (4%)
Haemorrhagic stroke 8(9%) 10 (9%)
Cardiovascular co-morbidity 60 (67%) 66 (58%)
Barthel score at admission: Means (SD) 10.8 (6.17) 9.5 (6.19)
Median (Range) 11.5 (0-20) 9 (0-20)
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Figure 1 Relation between EuroQol-5 D, Barthel Index, and modified Rankin Scale (mRS) (4 categories) classification during follow-up.
Table 2 Estimates for the disability-stratified stroke-simulation model
Parameter Unit Data source Value*
Epidemiological measure:
Age distribution incident strokes Rate Jager [34] 8.46
All cause mortality Rate Statistics Netherlands [35] 33.0
Stroke mortality Rate 1.9
Cardiovascular mortality Rate 8.4
Death from stroke Ratio Herman [36]/Bamford [37] 0.21
Recurrent after mRS 0-3 Relative risk Hoogen [38]/Dennis [39]/Dutch TIA Trial [40]
first year <75 years 0.09
>75 years
subsequent years 0.05
Late death from mRS 4-5 Ratio Howard [41,42] 0.15
Death from cardiac disease after mRS 0-3 stroke Relative risk Dutch TIA Trial[40]/Howard [41,42] 0.038
after mRS 4-5 stroke Relative risk Howard [41,42] 0.06
Utility weights for stroke disability categories - EDISSE data [14] 0-1
Disability after stroke (first-ever and recurrent) mRS 1-5
Hazard ratios:
Excess cardiovascular death mRS 0-1:mRS 2-3 Hazard ratio LiLAC study Group [18] 1.25†
mRS 4:mRS 5 Hazard ratio 1.25
Recurrent stroke mRS 0-1:mRS 2-3 Hazard ratio 1.34
mRS 4:mRS 5 Hazard ratio 1.34
Note: * number per 1,000 or probability for men aged 70-75. † The ratio reported in the Lilac study concerned all vascular events. We assume that the hazard
ratio is equal for both cardiovascular event and other vascular events.
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probabilities; (ii) number of patients in each disability
category and all events (i.e., transitions); (iii) average
survival time/life expectancy; (iv) quality-adjusted life
expectancy after stroke, defined as the number of survi-
val years multiplied with individual utility values from
the EDISSE trial.
Selection of outcome measures
The economic evaluation compares lifetime health
effects and costs of the stroke service as compared to
usual stroke care.
Health effects
Lifetime health effects were assessed as quality-adjusted
life years (QALYs) after stroke, measured with the Euro-
QoL-5 D [19]. Cost-effectiveness evaluations that take a
societal perspective make use of general public valua-
tions of these health states, available from Dutch
research [20]. EuroQol-5 D scores were rescaled, using
tariff scores, so that the maximum value of 1 represents
perfect health and the value 0 represents death; some
health states receive a value lower than 0, and are thus
considered worse than death by the general public. The
EuroQoL-5 D is short and simple enough so that most
stroke survivors, despite disabilities, can complete it
without help [19]. However, most are physically or men-
tally not able to (self-) report quality of life in the acute
phase after stroke. Therefore, no EuroQoL-5 D scores
were available from the EDISSE study at baseline. As in
a former study [14,21], scores on the Barthel Index (BI)
[22] were used to estimate EuroQoL-5 D scores at base-
line to ascertain that quality of life was measured at the
acute phase, i.e. the first six months (see Figure 1c).
Based on linear regression analysis, health-related qual-
ity of life was -0.25 for patients with BI score 0, and
increased by 0.05 with each additional BI point. Inde-
pendent patients (BI score 20) get a health-related qual-
ity of life equal to 0.75 [21].
Costs
Lifetime costs after stroke were restricted to direct med-
ical costs (i.e., a health care perspective), and computed
separately for the four disability categories (see below).
This excludes productivity costs as the strokes occurred
in elderly patients. We considered the impact on infor-
mal care in this study elsewhere [14]. Costs of care for
the first six months after stroke were based on patient
level resource use from the EDISSE study [13], and
resource costs/prices of 2003 [23]. Because length of
stay at different locations was the most important cost
driver during this period [13], first, inpatient costs were
calculated using original length of stay data and 2003
nursing day prices. Subsequently, total individual costs
of care during the first six months were computed by
holding the original ratio between inpatient and total
costs constant, for each patient and each place of
residence (hospital, nursing home, revalidation centre
and home) at which the patient stayed during this per-
iod, weighted by the length of stay. Costs of care for the
second half year after stroke were based on place of
residence data six months after stroke from the EDISSE
study and 2003 resource costs/prices. Costs in subse-
quent years were based on available data on the distri-
bution of patients by residence location [24]. Therefore,
after the first half year, costs are assumed not to differ
between stroke service and usual care. In accordance
with guidelines, differential discounting was applied with
an annual rate of 1.5% for health effects an 4.0% for
costs of care. This accounts for the increasing value of
health over time. Equal discount rates for costs and
health effects lead to sub-optimal societal results [25].
Cost-effectiveness analysis
The stroke service was compared to usual care by doing
the same lifetime extrapolation for both groups, simulta-
neously. Patient level data (i.e., level of initial stroke dis-
ability, costs, and health effects) were entered in a
probabilistic analysis, using a Microsoft Excel add-in:
Palisade’s @Risk. The runs were executed by a bootstrap
from the stroke service data. In each iteration, a patient
from the usual care data set was matched with the one
selected from the intervention region, according to age
and level of initial stroke disability. Stroke patient
entered the life-table at age 60, 70 or 80, based on the
known age distribution of first-ever stroke occurrence.
The runs resulted in estimates of lifetime health out-
comes (QALYs) and lifetime costs (Euros) in both arms.
Lifetime differences in costs and health effects were
compared by means of an incremental cost-effectiveness
ratio (ICER) of stroke service care as compared to usual
care, i.e., the difference in costs between the two settings
divided by the difference in effect. Incremental costs and
health effects were plotted in a cost-effectiveness plane,
and confidence intervals (5%, 50%, 90%) were computed
around the central point using the life table in 10.000
iterations. Sensitivity analysis was conducted using 3%
and 0% discounting rates for both costs and health
effects.
Results
Lifetime costs and health effects
Table 3 presents the average (half) yearly costs and the
EuroQoL-5 D score at discharge and 6 months after
stroke, differentiated stroke disability level, care setting
and gender, which were used to estimate lifetime costs
and health effects. These results show that patients trea-
ted in the experimental setting were on average in better
health. The first six months after stroke showed costs
reductions. Highest reductions showed inside the hospi-
tal. Here costs are reduced from €10,018 to €5,777, on
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average. This confirms earlier findings on the reduced
length of stay [13].
Life expectancy after stroke of patients in mRS cate-
gories 0-1, 2-3, 4 and 5 was 5.94, 5.16, 3.87 and 3.64 for
men, and 6.91, 5.94, 4.92, and 4.51 for women. Corre-
sponding lifetime QALYs were estimated at 4.12, 3.00,
1.39, -.02 for men, and 4.80, 3.28, 1.69, -0.01 for
women, respectively. Figure 2 shows that lifetime costs
and quality-adjusted life expectancy decrease with age,
both among men and women. Furthermore, the figure
shows that stroke services likely are cost saving, while
generating more QALYs. The lower costs in stroke ser-
vices resulted from shorter mean length of stay in hospi-
tal in the acute phase after stroke (13 vs. 29 days [13]),
and the lower proportion of patients who were institu-
tionalized one year after stroke (14% vs. 23%).
The overall life time costs for men were € 32,284 in
the stroke service setting and € 39,335 in the control
setting while the life time QALYs were 2.92 and 2.42
respectively. For women both costs (€ 38,443 in the
stroke service and € 42,944 in the usual care) while the
life time QALYs were higher (3.33 and 2.75 years). Stan-
dardized for gender the results for the stroke service
were average costs of € 35.361 and 3.12 QALYs and for
the usual care setting €41,352 and 2.61 QALYs. So, in
all three cases stroke services are associated with lower
costs and higher life time QALYs, i.e. stroke services
dominate usual care.
Cost-effectiveness results
Figure 3 presents the reliability intervals for the lifetime
cost-effectiveness of the stroke service as compared to
usual care, with a central point representing a cost sav-
ing of € 5,990 and a QALY gain of 0.51. The point esti-
mate for the ICER is €11,685 saved per QALY gained;
€14,211 and €7,745 saved per QALY gained for men
and women respectively. The probability that the stroke
service intervention is both effective and cost saving is
over 90%. The ICER declines with age. In addition, Fig-
ure 3 shows a negative correlation between health
effects and costs as lower health care consumption and
better health are associated.
Discounting both costs and health effects at a 3% rate
lead to slightly lower ICERs of € 15,510 and € 8,423
saved per QALY gained for men and women, respec-
tively. Discounting both at 0% lead to ICER estimates of
€ 14,144 and € 7,401 saved per QALY gained for men
and women, respectively. The results therefore showed
robustness and consistency in all age specific outcomes:
mean health effects were larger and mean costs were
lower in the stroke service in all age groups, both gen-
ders, and with all three ways of discounting.
Table 3 Average costs and EuroQoL-5 D score by follow-up period, stroke disability, care setting and gender
Care
setting
mRS 0-1 mRS 1-2 mRS 4 mRS 5 Stroke
service
(mean)*
Usual
care
(mean)*
Number (%) At hospital discharge Stroke
service
28 (25) 40 (35) 31 (27) 15 (13) - -
Usual care 14 (16) 40 (44) 29 (32) 7 (8) - -
Six months after hospital discharge Stroke
service
22 (14) 42 (66) 23 (15) 3 (5) - -
Usual care 16 (24) 75 (47) 17 (26) 6 (3) - -
Costs (in Euros, 2003) 0-6 months (including hospital
care)
Stroke
service
8,400 11,080 29,664 27,371 21.665 -
Usual care 9,856 14,868 37,628 46,089 - 24.837
0-6 months (excluding hospital
care)
Stroke
service
3,434 5,805 23,007 20,428 15.888 -
Usual care 3,181 6,603 22,430 21,930 - 14.819
7-12 months Both 1,761 4,196 17,824 22,515 9.633 9.826
after 1 year (men, 6-monthly costs) Both 811 1,028 5,997 7,633 3.109 3.233
after 1 year (women, 6-monthly
costs)
Both 811 1,028 9,900 12,702 4.761 4.990
Health-related quality of
life
at discharge Stroke
service
0.7500 0.6245 0.1667 -0.1739 0.3701 -
Usual care 0.7500 0.6163 0.2238 -0.1413 - 0.4201
after 6 months Stroke
service
0.8979 0.7726 0.6758 0.3030 0.7111 -
Usual care 0.8233 0.6863 0.5351 0.2371 - 0.6239
Note: * Weighted average over four stroke disability categories.
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Discussion
Our analysis presented mRS-stratified lifetime costs and
health effects after stroke and showed that stroke service
interventions most likely will lead to health benefits and
cost savings when considering lifetime outcomes. Our
results imply that the beneficial short term effect of
stroke services is not offset by a long term costs of
treatment and care because of longer survival.
The estimated health gain from stroke service imple-
mentation is substantial (about half a QALY), especially
as compared to the total number of QALYs usually
lived after a stroke (on average 2.42 for men and 3.33
for women in usual care). The estimated lifetime cost
savings of € 5,776 (14%) from stroke service implemen-
tation are also substantial. Although we did not incorpo-
rate start up and nationwide implementation costs, the
figures compare very well to recent figures by Struijs
et al. [4], who estimated that a nationwide implementa-
tion of stroke services in the Netherlands would result
in a 13% reduction of the costs of stroke as compared
with a regular care scenario.
The lifetime cost-effectiveness of stroke service imple-
mentation is comparable to the short-term (first
6 months after stroke) results presented by us in an earlier
study using the same trial data [14]. While the “lifetime
ICER” was € 11,685 saved per QALY gained, with a 90%
likelihood of the stroke service being cost saving. The
“short-term” ICER was € 19,350 saved per QALY gained,
Figure 2 Lifetime costs (in Euros) and health-related quality of life after stroke; mean values (90% CI) by age and gender.
Figure 3 Cost-effectiveness plane; reliability intervals (5%,
50%, 90%) for lifetime cost-effectiveness of stroke services as
compared to usual stroke care.
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with an 80% likelihood of the stroke service being lower
than €.35,000 per QALY gained. Our lifetime outcomes
after stroke show less cost savings but do therefore pro-
vide further support that stroke services are the organisa-
tion of choice as compared to usual fragmented care.
Stroke unit reviews use other outcome measures than
ICERs. The Cochrane library nor the HEED data base
report reviews of stroke unit cost-effectiveness evalua-
tions, but the reviews on their effectiveness is strong
[26]. The results of other studies ranged from a reduc-
tion of a relative risk of dependency for stroke patients
of 9% [27], to a 28 week cost reduction of € 567 [11].
Two cost-effectiveness studies showed results ranging
from 16,790 €/QALY gained [28] in the Netherlands to
90,699 €/QALY gained (64,097 £/QALY gained) [12] in
the UK. The latter study [12] compared three alternative
strategies but lacked a comparison with usual care.
We have made some critical choices in our evaluation.
The EDISSE study included three experimental and
three usual care settings. We analyzed data on all three
usual care settings, but limited ourselves to the only
real-life experiment that implemented a stroke service
completely according to national guidelines [14]. So, our
results are only valid for similar settings (a single hospi-
tal with supporting follow-up services). Our results may
therefore be optimistic and limit the options for wide
implementation as there are many settings with more
hospitals and a diversity of stroke rehabilitation services.
We would have included the (negative) results from the
other two settings only if the service model would have
turned out similar.
Next, we have not included indirect cost. Earlier [13]
we showed that there was an increase in home-based
and ambulatory health care cost (through professional
support and increased revalidation efforts). It might be
that the service set-up leads to additional cost of infor-
mal care and patients are discharged earlier. We cannot
confirm that this is not happening. In other studies [29]
it is explained that these cost are relatively low, also
after valuation. It is our expectation that these would
not alter the conclusion of our cost-effectiveness analy-
sis, also when taking this societal perspective.
Some comments are to be made on the stroke model
life tables. First, our model synthesizes data from differ-
ent studies and settings (see Table 2), giving a popula-
tion level estimates of the stroke burden. This approach
is similar to two recent UK studies [15,16] with all three
studies arriving at comparable conclusions (although the
latter applies only a ten year time horizon). Data on
mortality, hospitalization, and nursing home admission
rates were available from existing studies. The hazard
ratios for recurrent stroke and excess cardiovascular
death, however, were only available for patients with a
score on the mRS of 3 or lower. In the model, the same
hazard ratios were used to differentiate between mRS 4
and mRS 5 patients as between mRS 0-1 and mRS 2-3
patients. These assumptions do not influence the cost-
effectiveness results.
Second, the classification of patients at baseline was
based on the mapping of Barthel Index scores on Ran-
kin scale categories, because the mRS is less reliable in
the acute clinical phase after stroke. Although the corre-
lation between the measures was large, the chosen pro-
cedure may have led to some misclassification of
patients, resulting in higher uncertainty in survival
outcomes.
Third, the bootstrap conducted for each age group
and gender was based on the same patients. Patients
were not entered by age and gender due to sample size
limitations, which means that it was assumed that the
effect of stroke and stroke treatment is independent of
age and gender [30]. While it is still unclear how the
impact of a stroke on an individual’s quality of life varies
by age [31,32], this does not mean that quality of survi-
val is equal for different ages and gender, as assumed in
the model. This is expected to have more effect on the
lifetime outcomes differentiated per age and gender,
than on total outcomes.
Finally, the results presented here were based on a
life-table extrapolation of data originating from studies
with sometimes short follow-up periods. For a more
accurate estimate of the lifetime cost-effectiveness of
stroke services, it would be necessary to conduct similar
studies with a much longer follow-up. These do not
exist (yet). Nonetheless, the disability stratified model
presented here is the most comprehensive and detailed
analysis currently available for estimating the lifetime
health and costs after stroke for The Netherlands.
Summarizing, this study confirms previous findings
that, from a health care perspective, effective coordina-
tion between health care providers involved in the reha-
bilitation of stroke patients, through integrated stroke
services, may result in positive lifetime health effects at
lower costs. Previous studies described the effects of
interventions limited to early stage stroke units. Our
study included the additional long-term health effect
and organization effects associated with extra coordina-
tion between different health care organizations opposed
to coordination within a single organization.
Our findings support the recommendations of the
European Stroke Initiative to provide disabled stroke
patients with early institutionalized rehabilitation by a
multidisciplinary team [33]. However, length of stay in
stroke units may vary within Europe and this may
change the financial, short-term, impact of stroke ser-
vices outside the Netherlands. Likewise, case load and
severity may be dissimilar in different settings. Unlike in
many European countries treatment for stroke patients
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in specialized hospital units is common in the Nether-
lands. The intervention effect measured in this study,
taking the Delft example, is very likely an underestima-
tion of the potential much larger impact of stroke ser-
vice introduction in countries without specialized
hospital stroke care. In sum, although transferability of
stroke services set-ups to different setting needs to be
accounted for, both in health and economic terms, we
do recommend implementation of stroke services in a
wider array of country settings.
Additional material
Additional file 1: Life-table equations. Additional file 1 describes the
generic equations used in the disease model for the calculation of the
transition probabilities between disease states. It also describes the
equation used to estimate the life-tables outcomes, i.e. average quality of
life and average health care costs.
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